All In Biotech

Drug Trial Radar · NCT07397325

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

May 16, 2026

Primary completion

Feb 5, 2027

Study completion Mar 5, 2027

Sponsor

Lead sponsor
Applied Biology, Inc.Industry
Sponsor type
Industry
Collaborators
Daniel Alain, Inc.; Follea International Limited
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia

Conditions

  • Chemotherapy Induced Alopecia
  • Chemotherapy Side Effects

Interventions

  • DA-020Drug

    7mL application of DA-020 (Topical Oxymetazoline)

  • PlaceboDrug

    Topical placebo solution

  • DA-020 and HyperforinDrug

    7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevention of Hair Loss (Common Terminology Criteria for Adverse Events V5.0)Time frame: Week [0,12]

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Samel

    Manaus, Brazil · Recruiting

  • University of Rome ("G. Marconi")

    Rome, Italy · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.